With 170 million children and adolescents now living with obesity — four times the 1990 prevalence — the World Health Organization has issued its first global treatment guidelines for under-20s. They rule out weight-loss medicines and surgery for children under ten and treat them as a last resort for adolescents.
For years, paediatricians have treated childhood obesity with a patchwork of national advice, and families have increasingly heard about weight-loss injections designed for adults. On Wednesday, 7 October, the World Health Organization (WHO) published its first global guidelines on the integrated management of obesity in children and adolescents, setting out what health systems and health workers should — and should not — offer young people living with the condition.
The scale of the problem explains the urgency. According to WHO, 170 million people aged five to 19 were living with obesity in 2024: about 70 million aged five to nine and 100 million aged ten to 19. Prevalence in this age group has quadrupled since 1990, from 2 per cent to 8 per cent.
“The foundation of obesity care for children and adolescents is not medicine or surgery,” said Dr Luz María De Regil, Director of WHO’s Department of Nutrition and Food Safety, emphasising instead comprehensive support for healthy eating, physical activity and lasting behaviour change.
Defining the problem
For children and adolescents, obesity is not defined by a fixed body-mass index (BMI) cut-off, as it is for adults. WHO classifies a child aged five to 19 as living with obesity when BMI-for-age lies more than two standard deviations above the median of the WHO growth reference. This age- and sex-specific approach matters clinically: a child’s healthy weight changes as they grow, and treatment decisions must account for growth and puberty. It also explains why WHO frames care as long-term management rather than a short course of weight loss, and why it insists on family involvement — young children rarely control what food enters the home.
What the guidelines recommend
The guidance is published as two documents, one for children and one for adolescents, and follows WHO’s standard process of grading recommendations by the strength of evidence.
For all children and adolescents with obesity, WHO makes a strong recommendation for structured dietary, physical-activity and behaviour-change interventions, delivered individually or as part of a multimodal programme. Digital health tools — apps, online coaching and similar — receive a conditional recommendation, provided parents or caregivers supervise their use.
For children up to nine years old, WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices.
For adolescents aged ten to 19, approved medicines may be considered, but only after a supervised multimodal lifestyle programme has failed to achieve the desired results. Bariatric surgery may be considered under strict conditions for adolescents with severe obesity.
The WHO announcement does not name individual drugs. In practice, the medicines debate centres on GLP-1 receptor agonists such as semaglutide and liraglutide, which some regulators have approved for adolescents in recent years and which have generated intense demand worldwide. The guidelines effectively place such drugs as second-line options for teenagers and outside the scope of care for younger children.
Beyond the scales
Two principles run through the document. First, mental health and obesity should be addressed early and together. Children living with obesity face higher rates of anxiety, depression and bullying, and WHO asks health workers to use inclusive, developmentally appropriate and family-engaged approaches rather than stigmatising ones. Second, the goal of care is improved health, functioning and well-being, not weight loss alone, with long-term follow-up rather than short courses.
WHO is also explicit that clinics cannot solve the problem by themselves. “Treatment alone” cannot reverse the rise in obesity, the organisation says, calling for policies that make healthy diets and physical activity more accessible and affordable: regulatory and fiscal measures, and action through education, urban planning, transport and social protection. The new guidelines complete a life-course approach alongside WHO’s existing adult obesity recommendations and its acceleration plan to stop obesity.
Why caution on drugs?
The restriction on medicines for young children reflects both evidence and uncertainty. Trials of newer obesity drugs in children are limited, long-term effects on growth, puberty and bone development are not well characterised, and weight usually returns when treatment stops — which, for a child, could mean decades of therapy. For adolescents, trials have shown meaningful weight reduction, which is why WHO leaves the door open, but under supervision and after lifestyle measures. Critics of a lifestyle-first approach argue that such programmes are often unavailable, especially in low-resource settings, and that delaying effective treatment carries its own risks. WHO’s emphasis on structural policy is in part an answer to that concern.
What it means for India
India is confronting a double burden: persistent undernutrition alongside rising overweight and obesity, particularly in urban and higher-income households. A 2024 analysis in The Lancet by the NCD Risk Factor Collaboration estimated that about 12.5 million Indian children and adolescents aged five to 19 were living with obesity in 2022. School canteens, packaged-food marketing, reduced outdoor play and long screen hours are recurring drivers identified by Indian researchers.
The guidelines arrive as interest in GLP-1 weight-loss drugs grows rapidly in India. Paediatricians and parents will now have a clear international reference against using them in young children. The policy recommendations are equally relevant: front-of-pack labelling of foods high in fat, sugar and salt, which India’s food regulator has been considering for years; school nutrition and physical-education standards; and urban design that makes walking, cycling and play safe.
The guidelines will be judged by implementation. Their success depends on whether governments train primary-care workers, fund family-based programmes and take on the commercial food environment — tasks far harder than writing a prescription.
–Rithvisha Kiran
Key facts
- Published: 7 October 2026, WHO’s first global guidelines on child and adolescent obesity (two documents)
- Burden (2024): 170 million aged 5–19 with obesity (70 m aged 5–9; 100 m aged 10–19); prevalence up from 2% (1990) to 8%
- Strong recommendation: structured diet, physical-activity and behaviour-change interventions; conditional recommendation for supervised digital tools
- Ages 0–9: no medicines, bariatric surgery or devices; ages 10–19: medicines only after supervised lifestyle programme; surgery only under strict conditions for severe obesity
- Policy: fiscal and regulatory measures; action in education, urban planning, transport and social protection
